Hepatitis B and C Diagnostics

A Global Strategic Business Report

MCP37076

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

7416

EXECUTIVE POOL

5850

PRICE

812

EXPERT INPUTS

44

COMPANIES

201

DATA TABLES

275

PAGES

2

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (55)

3

CXO

5

VICE PRESIDENT

10

DIRECTOR

25

MANAGER

12

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Hepatitis B and C Diagnostics Market to Reach US$9.6 Billion by 2030

The global market for Hepatitis B and C Diagnostics estimated at US$6.8 Billion in the year 2024, is expected to reach US$9.6 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Immunodiagnostics, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Nucleic Acid Testing segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 9.1% CAGR

The Hepatitis B and C Diagnostics market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Hepatitis B and C Diagnostics Market – Key Trends & Drivers Summarized

Are Innovations in Diagnostic Technology Changing the Outlook for Hepatitis Detection?

The diagnostics landscape for Hepatitis B and C is undergoing a fundamental transformation driven by rapid advancements in medical technology, molecular biology, and point-of-care testing. These two forms of viral hepatitis, which collectively affect hundreds of millions worldwide, have long posed diagnostic challenges due to asymptomatic progression, limited screening in vulnerable populations, and the complexity of viral behavior in chronic cases. However, new technologies are now enabling earlier, faster, and more accurate detection of both HBV and HCV. Molecular assays, particularly nucleic acid amplification tests (NAATs), are emerging as the gold standard for confirming active viral infection and monitoring viral load. These tests offer high sensitivity and specificity, capable of identifying even low levels of viral RNA or DNA, which is critical for guiding treatment decisions. Simultaneously, advances in serological testing, including enzyme-linked immunosorbent assays (ELISA) and rapid diagnostic tests (RDTs), are making population-level screening more feasible, especially in low-resource settings. Innovations such as dried blood spot (DBS) testing, multiplex platforms, and automated immunoassay systems are increasing throughput while reducing turnaround times. The rise of digital diagnostics, including AI-assisted test interpretation and mobile-integrated diagnostic readers, is also extending access to underserved communities and improving data collection for public health interventions. Collectively, these innovations are pushing Hepatitis B and C diagnostics beyond hospital laboratories and into primary care, community clinics, and remote health centers-making early intervention, prevention of transmission, and disease management more achievable than ever before.

Is the Global Push for Elimination Driving Widespread Hepatitis Screening Initiatives?

Global public health initiatives, particularly those spearheaded by the World Health Organization (WHO), are playing a crucial role in elevating hepatitis diagnostics as a top healthcare priority. With WHO’s ambitious goal to eliminate viral hepatitis as a public health threat by 2030, countries are being urged to scale up screening, diagnosis, and linkage to care-especially among high-risk populations such as people who inject drugs, prisoners, sex workers, and individuals living with HIV. In response, governments and non-governmental organizations are ramping up community-based testing programs, mobile health units, and targeted outreach campaigns designed to increase diagnosis rates. As part of this effort, public health policies are increasingly mandating routine hepatitis testing in antenatal care, blood donations, and healthcare worker screenings, helping to normalize testing and reduce associated stigma. Additionally, funding from global health organizations such as the Global Fund, Gavi, and UNITAID is enabling developing countries to procure advanced testing technologies, improve laboratory capacity, and integrate hepatitis diagnostics into existing healthcare infrastructure. Regional partnerships in Asia-Pacific, Africa, and Latin America are also fostering knowledge sharing and standardized guidelines to ensure that testing strategies are both efficient and equitable. The adoption of simplified diagnostic algorithms-such as reflex testing and one-step confirmatory protocols-is further accelerating the path from screening to treatment initiation. Educational campaigns and awareness drives are playing a crucial role in encouraging individuals to get tested, particularly in communities where hepatitis remains poorly understood. This coordinated global movement is reshaping the diagnostics market, driving both volume and innovation as testing becomes a cornerstone of hepatitis elimination strategies worldwide.

How Are Decentralized Testing and Point-of-Care Solutions Expanding Access to Diagnostics?

The growing availability of decentralized and point-of-care (POC) diagnostic tools is dramatically expanding access to Hepatitis B and C testing, particularly in resource-limited and rural areas where laboratory infrastructure is minimal or nonexistent. These compact, easy-to-use diagnostic kits are revolutionizing outreach by enabling frontline health workers to conduct testing outside of traditional medical settings, such as in homes, schools, community centers, and refugee camps. POC tests based on lateral flow immunoassay technology allow for rapid detection of HBV surface antigen (HBsAg) or HCV antibodies with results in as little as 15 to 30 minutes. Many of these tests require only a finger-prick blood sample and do not rely on refrigeration, making them ideal for deployment in tropical or underserved regions. Moreover, advances in microfluidics, biosensors, and battery-powered analyzers are improving the accuracy and reliability of these decentralized tools, narrowing the performance gap between POC tests and centralized laboratory assays. Integration of POC testing with digital health platforms enables immediate recording and transmission of results, which facilitates real-time disease surveillance and follow-up care. In humanitarian settings and remote communities, task-shifting models-where trained non-physician health workers conduct screenings-are further increasing testing coverage and efficiency. The affordability of these solutions is also improving, with global procurement initiatives ensuring reduced-cost diagnostics for high-burden countries. This democratization of access is especially vital in achieving early diagnosis and intervention, reducing the time from detection to treatment, and supporting broader hepatitis elimination targets. As decentralized testing technologies continue to evolve, their role in overcoming logistical, financial, and geographic barriers to hepatitis care will only become more central.

What Key Market Forces Are Fueling Growth in the Hepatitis B and C Diagnostics Sector?

The growth in the Hepatitis B and C diagnostics market is driven by several factors rooted in rising disease prevalence, technological innovation, healthcare policy evolution, and shifting patterns in consumer behavior and provider priorities. The sheer scale of the global hepatitis burden-over 350 million individuals living with chronic HBV or HCV-provides a significant base for diagnostic demand, especially as treatment eligibility increasingly depends on precise viral quantification. Aging populations, rising rates of injection drug use, and increased migration from high-prevalence countries are further expanding the at-risk demographic. On the technological front, the emergence of next-generation molecular platforms, digital immunoassays, and AI-powered diagnostic analytics is accelerating test accuracy, speed, and affordability. Meanwhile, pharmaceutical advancements-particularly the availability of curative direct-acting antivirals (DAAs) for hepatitis C-are motivating more patients to seek diagnosis, creating a feedback loop of demand between treatment and diagnostics. Regulatory bodies across Europe, North America, and Asia are implementing screening mandates in blood banks, prenatal care, and hospital admissions, institutionalizing the role of hepatitis testing in public health policy. Concurrently, global investments in diagnostic infrastructure-bolstered by pandemic-era capacity building-are being repurposed to expand hepatitis testing. Consumer behavior is also changing; increased health literacy, the normalization of self-testing, and digital health tools are empowering individuals to proactively seek testing. Private diagnostic laboratories, telehealth services, and at-home testing kits are responding with customized services, further diversifying access. Combined, these forces are shaping a rapidly evolving market that is as much about innovation and access as it is about medical necessity-positioning hepatitis diagnostics as a critical frontier in the global fight against infectious diseases.

SCOPE OF STUDY

The report analyzes the Hepatitis B and C Diagnostics market by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Immunodiagnostics, Nucleic Acid Testing); Disease Type (Hepatitis B, Hepatitis C).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..

SELECT PLAYERS

Abbott Laboratories; Affymetrix (Thermo Fisher); Becton, Dickinson and Company; Bio-Rad Laboratories; Biomerieux SA; Cepheid (Danaher); DiaSorin S.p.A.; Fujirebio (H.U. Group); Grifols, S.A.; Hologic, Inc.; HORIBA, Ltd.; InTec Products, Inc.; Johnson & Johnson; MedMira Inc.; Ortho Clinical Diagnostics; Qiagen N.V.; Roche Diagnostics; Siemens Healthineers; Sysmex Corporation; Trinity Biotech;

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

World Market Trajectories

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Hepatitis B and C Diagnostics – Global Key Competitors Percentage Market Share in 2025 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 44 Players Worldwide in 2025 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Global Burden of Chronic Hepatitis Infections Throws the Spotlight on Early and Accurate Diagnostics

Increased Government-Led Screening Initiatives Propel Growth in Population-Wide Testing Programs

Global Commitment to Viral Hepatitis Elimination Expands Addressable Market for Diagnostic Solutions

Advancements in Rapid Point-of-Care Testing Drive Adoption in Resource-Limited Settings

Integration of Molecular Diagnostics Strengthens Business Case for High-Sensitivity Viral Load Testing

Growing Public Health Focus on Blood Safety Generates Demand for Routine Hepatitis Screening

Widespread Use of Combination Panels and Multiplex Testing Spurs Efficiency in Diagnostic Workflows

Technological Innovation in PCR and Next-Generation Sequencing Accelerates Diagnostic Accuracy

Increased Access to Affordable Diagnostics Through Global Health Partnerships Sustains Market Growth

Expansion of At-Home and Self-Testing Solutions Drives Consumer-Centric Hepatitis Testing

Healthcare Digitization and Data Integration Throw the Spotlight on Real-Time Epidemiological Tracking

Rising Co-Infection Risks with HIV and TB Generate Demand for Integrated Diagnostic Platforms

Lack of Awareness and Underdiagnosis in Low-Income Regions Pose Persistent Challenges to Market Penetration

4. GLOBAL MARKET PERSPECTIVE

World Hepatitis B and C Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

World Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Hepatitis B and C Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Immunodiagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Immunodiagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Immunodiagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Nucleic Acid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Nucleic Acid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Nucleic Acid Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Hepatitis B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Hepatitis B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Hepatitis B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

World Recent Past, Current & Future Analysis for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

World 16-Year Perspective for Hepatitis C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

USA 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

USA Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

USA 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Canada 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Canada 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

JAPAN

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Japan 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Japan 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

CHINA

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

China 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

China Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

China 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

EUROPE

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Review for Hepatitis B and C Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

FRANCE

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

France 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

France Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

France 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

GERMANY

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Germany 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Germany 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Italy 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Italy 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

UNITED KINGDOM

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

UK 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

UK Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

UK 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

SPAIN

Spain Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Spain 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Spain 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

RUSSIA

Russia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Russia 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Russia 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Rest of Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Rest of Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

ASIA-PACIFIC

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

AUSTRALIA

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)

Australia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Australia 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Australia 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

INDIA

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)

India Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

India 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

India Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

India 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

SOUTH KOREA

South Korea Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

South Korea 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

South Korea 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

REST OF ASIA-PACIFIC

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Rest of Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Rest of Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

LATIN AMERICA

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)

Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Latin America Historic Review for Hepatitis B and C Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

ARGENTINA

Argentina Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Argentina 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Argentina 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

BRAZIL

Brazil Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Brazil 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Brazil 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

MEXICO

Mexico Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Mexico 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Mexico 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

REST OF LATIN AMERICA

Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Rest of Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Rest of Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

MIDDLE EAST

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)

Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Middle East Historic Review for Hepatitis B and C Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

IRAN

Iran Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Iran 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Iran 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

ISRAEL

Israel Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Israel 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Israel 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

SAUDI ARABIA

Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Saudi Arabia 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Saudi Arabia 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

UNITED ARAB EMIRATES

UAE Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

UAE 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

UAE 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

REST OF MIDDLE EAST

Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Rest of Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Rest of Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

AFRICA

Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)

Africa Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Africa 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR

Africa 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Clinical Laboratories Pty Limited	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll